EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

Lucía González-Pinto iD, Isaac Alonso-García iD, Tania Blanco-Martín iD, Pablo Camacho-Zamora, Pablo Arturo Fraile-Ribot iD, Michelle Outeda-García iD, Cristina Lasarte-Monterrubio iD, Paula Guijarro-Sánchez iD, Romina Maceiras, Bartolome Moya iD, Carlos Juan iD, Juan Carlos Vázquez-Ucha iD und 4 weitere

Journal of Antimicrobial Chemotherapy · 01.10.2024 · 79 (10) · 2591-2597

DOI: 10.1093/jac/dkae263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 29.07.2024. Verfasst von Lucía González-Pinto und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Cephalosporins, Microbial Sensitivity Tests, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Merck Sharp & Dohme, Investigator Initiated Studies Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to compare the stability of the newly developed β-lactams (cefiderocol) and β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam/avibactam, cefepime/taniborbactam, cefepime/zidebactam, imipenem/relebactam, meropenem/vaborbactam, meropenem/nacubactam and meropenem/xeruborbactam) against the most clinically relevant mechanisms of mutational and transferable β-lactam resistance in Pseudomonas aeruginosa.

Methods

We screened a collection of 61 P. aeruginosa PAO1 derivatives. Eighteen isolates displayed the most relevant mechanisms of mutational resistance to β-lactams. The other 43 constructs expressed transferable β-lactamases from genes cloned in pUCP-24. MICs were determined by reference broth microdilution.

Results

Cefiderocol and imipenem/relebactam exhibited excellent in vitro activity against all of the mutational resistance mechanisms studied. Aztreonam/avibactam, cefepime/taniborbactam, cefepime/zidebactam, meropenem/vaborbactam, meropenem/nacubactam and meropenem/xeruborbactam proved to be more vulnerable to mutational events, especially to overexpression of efflux operons. The agents exhibiting the widest spectrum of activity against transferable β-lactamases were aztreonam/avibactam and cefepime/zidebactam, followed by cefepime/taniborbactam, cefiderocol, meropenem/xeruborbactam and meropenem/nacubactam. However, some MBLs, particularly NDM enzymes, may affect their activity. Combined production of certain enzymes (e.g. NDM-1) with increased MexAB-OprM-mediated efflux and OprD deficiency results in resistance to almost all agents tested, including last options such as aztreonam/avibactam and cefiderocol.

Conclusions

Cefiderocol and new β-lactam/β-lactamase inhibitor combinations show promising and complementary in vitro activity against mutational and transferable P. aeruginosa β-lactam resistance. However, the combined effects of efflux pumps, OprD deficiency and efficient β-lactamases could still result in the loss of all therapeutic options. Resistance surveillance, judicious use of new agents and continued drug development efforts are encouraged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaCephalosporinsMicrobial Sensitivity Testsbeta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsDrug CombinationsCefiderocolCyclooctanesTazobactambeta-LactamsHumansbeta-Lactam ResistanceCeftazidimePseudomonas InfectionsGene Transfer, HorizontalChromosomes, Bacterial

Substanzen

Cephalosporinsbeta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsDrug CombinationsCefiderocolCyclooctanesTazobactambeta-Lactams

Autor:innen und Institutionen

  • Servicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • Servicio de Microbiología & Instituto de Investigación Sanitaria Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Lucía González-Pinto, Isaac Alonso-García, Tania Blanco-Martín, Pablo Arturo Fraile-Ribot, Michelle Outeda-García, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, Bartolome Moya, Carlos Juan, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Germán Bou, Jorge Arca-Suárez

Förderung

  • European Union
  • Merck Sharp & Dohme
  • Investigator Initiated Studies Program
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
  • Spanish Network of Research in Infectious Diseases
  • National Plan for Scientific Research, Development and Technological Innovation 2013-2016
  • ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund
  • Axencia Galega de Innovación

Zitieren

APA

González-Pinto, L., Alonso-García, I., Blanco-Martín, T., Camacho-Zamora, P., Fraile-Ribot, P. A., Outeda-García, M., Lasarte-Monterrubio, C., Guijarro-Sánchez, P., Maceiras, R., Moya, B., Juan, C., Vázquez-Ucha, J. C., Beceiro, A., Oliver, A., Bou, G., & Arca-Suárez, J. (2024). Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 79(10), 2591-2597. https://doi.org/10.1093/jac/dkae263

Vancouver

González-Pinto L, Alonso-García I, Blanco-Martín T, Camacho-Zamora P, Fraile-Ribot PA, Outeda-García M, et al. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 2024;79(10):2591-2597. doi:10.1093/jac/dkae263

BibTeX
@article{GonzlezPinto2024,
  author = {González-Pinto, Lucía and Alonso-García, Isaac and Blanco-Martín, Tania and Camacho-Zamora, Pablo and Fraile-Ribot, Pablo Arturo and Outeda-García, Michelle and Lasarte-Monterrubio, Cristina and Guijarro-Sánchez, Paula and Maceiras, Romina and Moya, Bartolome and Juan, Carlos and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and Oliver, Antonio and Bou, Germán and Arca-Suárez, Jorge},
  title = {Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {10},
  pages = {2591--2597},
  doi = {10.1093/jac/dkae263}
}
Kostenlos starten →